The 600-1100 nm Optical Window: Why Red and Near-Infrared Light Heal

Hold your hand up to a bright lamp. The flesh glows red. That red color is the only part of the visible spectrum that made it through your skin, your fascia, your capillary bed — every other wavelength was stopped at the surface. The band that gets through is roughly 600 to 1100 nanometers, and it is not a coincidence that this is also the band that heals. Your tissue and your mitochondria evolved on the same planet, under the same sun, and they negotiated a transparency window. Photobiomodulation runs through it.

The three chromophores that close the window

Light passing through biological tissue is filtered by three principal absorbers. Hemoglobin, in both oxygenated and deoxygenated forms, absorbs strongly below about 600 nm — that is why blood looks red, because it is selectively eating green and blue. Melanin, the dark pigment in skin and the iris, absorbs broadly across the UV and visible range with a long tail that decays into the red. Water, which makes up roughly 60 percent of soft tissue by mass, is essentially transparent across the visible range but begins absorbing meaningfully above 950 nm, and dominates beyond 1300 nm.^[1]

Plot those three curves on the same axes and you find a valley. Below 600 nm, hemoglobin closes the window. Above 1100 nm, water closes it. Across the intervening 500 nanometers — the optical window of tissue — light penetrates relatively unimpeded. R. Rox Anderson and John Parrish first published the formal optical map of human skin from the Wellman Center at Massachusetts General Hospital in 1981, in a paper that has been cited more than four thousand times and underwrites essentially every modern laser dermatology and photobiomodulation protocol.^[1]

How deep does which wavelength reach?

Within the optical window, penetration depth depends on the balance between absorption (chromophores eating photons) and scattering (collagen and lipid membranes redirecting them). The deeper into the red and near-infrared you go, the less the photons are absorbed, and the more they scatter forward instead of backward — meaning more of the original beam actually reaches deep tissue. Michael Hamblin's group at the Wellman Center published the canonical depth measurements:^[3]

Those numbers are half-attenuation depths — the depth at which half the photons have been absorbed or scattered out of the beam. Actual therapeutic depth reaches considerably further, because PBM does not require an intact beam: even a single photon hitting a single mitochondrion at the right wavelength can do work. Doubling the surface irradiance roughly doubles the maximum depth at which the effective fluence threshold is still crossed.

The biphasic dose-response: why more is not better

The most counterintuitive fact in photobiomodulation is that the dose-response curve is not monotonic. It is biphasic: at low doses, biological response increases with dose. At a peak dose, response is maximal. Beyond the peak, response decreases — and at sufficiently high doses, response inverts and the light becomes inhibitory. This pattern was observed empirically across hundreds of studies and was formalized by Huang, Chen, Carroll, and Hamblin in a landmark 2009 paper in Dose-Response.^[2]

The biological logic is the same logic that governs every hormetic response in physiology. A small reactive-oxygen-species pulse activates Nrf2 and upregulates the antioxidant machinery. A large ROS pulse causes oxidative damage. A small NO release vasodilates locally. A large NO release induces nitrosative stress. Mitochondria are exquisitely tuned dose-responders, and photobiomodulation rides exactly that curve.

This is also why photobiomodulation devices that simply maximize wattage tend to produce worse outcomes than devices that hit a calibrated therapeutic range. The Arndt-Schulz rule, named for the nineteenth-century pharmacologists Hugo Schulz and Rudolf Arndt who first articulated the biphasic principle for chemical agents, applies cleanly to photons.

The dosimetry parameters that actually matter

Two numbers describe the dose of any photobiomodulation session:

• Irradiance (mW/cm²) — the rate at which energy is delivered per square centimeter of skin. Typical therapeutic range: 5 to 100 mW/cm².
• Fluence (J/cm²) — the total energy delivered per square centimeter over the full session. Typical therapeutic range: 1 to 60 J/cm². Fluence equals irradiance multiplied by exposure time in seconds, divided by 1000.

For pain and tissue repair, the published sweet spot tends to sit around 1 to 10 J/cm² at 50 to 100 mW/cm² for sessions of 1 to 5 minutes per treatment site, two to five times per week, for 4 to 12 weeks. For deeper neurological indications — transcranial PBM for cognitive endpoints — fluence climbs to 20 to 60 J/cm² with longer sessions, because more of the delivered energy is lost to scattering before it reaches the cortex.^[2]

Tesla BioLights operates as a non-contact field-emission system at arm's-length distance, so its dosimetry is described in terms of total session energy and emission spectrum rather than spot-fluence. The 15-minute session was empirically calibrated by Doug to fall within the parasympathetic-activation, photobiomodulation-positive range — far below any thermal or inhibitory threshold, well within the multi-wavelength PBM band.

Laser vs LED: the coherence debate, mostly settled

For three decades, photobiomodulation was synonymous with low-level laser therapy (LLLT). Practitioners and equipment manufacturers argued that the coherence and monochromaticity of laser light were essential to the therapeutic effect. The argument made physical sense — coherent light maintains its phase relationships and can therefore exhibit quantum-coherence behavior in biological tissue — but it ran up against an awkward empirical fact. When researchers ran head-to-head comparisons of LED-based and laser-based devices at matched fluence, the biological responses were largely indistinguishable.^[4]

The current consensus, articulated in Hamblin's reviews and confirmed by multiple meta-analyses in Photonics & Lasers in Medicine and Lasers in Medical Science, is that coherence per se is not the operative variable. What matters is wavelength, fluence, and irradiance. LED arrays — which are vastly cheaper, safer, cooler-running, and more spatially uniform than laser diodes — produce equivalent results when properly calibrated.

The plasma emission inside a Tesla BioLights tube is neither laser nor LED. It is incoherent broadband line emission — the same physical process by which neon signs and fluorescent lamps emit, with a quantum-mechanically defined set of wavelengths specific to each noble gas. It is closer to LED than laser. The relevant variable for PBM is whether the emission wavelengths fall within the cytochrome c oxidase action spectrum, which (as covered yesterday) they do.

What the FDA has cleared, and what it tells us

The FDA's 510(k) database is the most informative source for which photobiomodulation parameters have been independently validated in formal clinical trials. The current landscape includes:

• HairMax LaserComb — 655 nm laser, 9 mW total output, cleared 2007 for androgenic alopecia. Successive devices have raised the diode count without changing the wavelength.
• LED panels for skin rejuvenation — typically combining 633 nm (red, for surface collagen) and 830 nm (NIR, for deep dermal fibroblasts). Cleared across multiple manufacturers (LightStim, Joovv, others) for periorbital wrinkle reduction.
• Theralase TLC-2000 — 660 nm and 905 nm dual wavelength, cleared for chronic neck and shoulder pain.
• LumiThera Valeda Light Delivery System — 590 nm, 660 nm, 850 nm. Cleared 2023 in the US for dry age-related macular degeneration following the LIGHTSITE trials. The first explicit ophthalmologic PBM clearance.
• Smartlux II — 660 nm and 850 nm, cleared for oral mucositis in pediatric cancer patients.

None of these are blockbuster pharmaceutical approvals. All of them are 510(k) clearances based on substantial-equivalence to predicate devices and disease-specific clinical evidence. They establish, collectively, that the agency considers the optical-window-cytochrome-c-oxidase pathway scientifically valid for several distinct indications.

Athletic recovery: the muscle-tissue evidence

Photobiomodulation in sports medicine sits in a slightly different evidentiary lane. Athletic teams are not the FDA — they need devices that produce measurable performance gains, fast recovery, and reduced injury risk in their actual athletes, and they vote with their training budgets.

Cleber Ferraresi and Michael Hamblin published the most comprehensive review of LLLT on muscle tissue in 2016 in Photonics & Lasers in Medicine, summarizing 46 randomized controlled trials demonstrating reduced delayed-onset muscle soreness, faster recovery of creatine kinase, reduced lactate accumulation, and improved performance on subsequent training bouts when PBM was applied pre- or post-exercise at typical wavelengths of 660 nm and 830-905 nm.^[4] The Cleveland Clinic Sports Health Center, the Andrews Sports Medicine Institute, and the U.S. Olympic training facilities have all integrated PBM into recovery protocols over the past decade.

What this means for Tesla BioLights

Three direct consequences for the S.E.A.D. System.

First, the noble-gas plasma inside each tube emits at multiple wavelengths simultaneously — argon's strongest visible-NIR lines at 696, 763, 811, 842, and 912 nm; xenon at 823, 882, 904 nm; krypton at 758 and 811 nm. Those wavelengths land directly in the half-attenuation zone for muscle belly, peripheral nerve, joint capsule, and (with sufficient irradiance and proximity) the parasympathetic-relevant vagal afferents in the neck and chest. The plasma delivers a multi-wavelength bath rather than a single-frequency exposure, which is exactly what the multi-target action spectrum of CCO is tuned to absorb.

Second, because Tesla BioLights operates at non-contact distance with calibrated session times of 15 minutes, the total fluence delivered to any one surface area sits firmly inside the lower-to-middle range of the published Arndt-Schulz curve. The system is designed to encourage hormetic response rather than to push the dose toward the inhibitory branch — which is what some high-intensity over-the-counter "red light therapy" panels risk doing when used for too long or too close.

Third, the simultaneous pulsed electromagnetic field — generated as a side effect of the high-frequency Tesla-coil drive — addresses the bioelectric layer (the substrate of Michael Levin's work) at the same time as the photonic layer addresses the metabolic one. Two channels, one fifteen-minute session.

Tomorrow on the Journal

Day 14 — Xenon and Argon Are Real Pharmacology. The peer-reviewed evidence on noble gas neuroprotection: xenon as a clinical anesthetic and NMDA antagonist, argon's HIF-1α pathway, the 2026 Journal of Translational Medicine review on noble gas biology, and why the gas inside a Tesla BioLights tube is doing pharmacological work even before it is ionized into plasma.